692. The Role of Fidaxomicin for the Treatment of Clostridioides Difficile Infection in the Pediatric Population in the United States

BACKGROUND: In 2020, the FDA approved fidaxomicin (FDX) for the treatment of Clostridioides difficile infection (CDI) in children 6 months and older. The latest IDSA/SHEA guidelines recommend FDX use for adults only. A survey presented at IDWeek 2022 showed that only 35% of institutions used FDX as...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yuman, Bradley, Nicole, Smith, Sarah, Rakhimova, Shakhzoda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679036/
http://dx.doi.org/10.1093/ofid/ofad500.754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679036/
http://dx.doi.org/10.1093/ofid/ofad500.754

Ejemplares similares